RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Vir Biotechnology Stock

Vir Biotechnology AAQS 2024

Vir Biotechnology AAQS

2

Ticker

VIR

ISIN

US92764N1028

WKN

A2PS0P

Vir Biotechnology has a current AAQS of 2.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Vir Biotechnology in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

Vir Biotechnology Aktienanalyse

What does Vir Biotechnology do?

Vir Biotechnology Inc. is a biopharmaceutical company focused on the development of therapeutics to combat infectious diseases. The company was founded in 2016 by George Scangos, former CEO of Biogen, and Bob Nelsen, co-founder of Arch Venture Partners. History: Vir Biotechnology originated from a collaboration between Arch Venture Partners and the biotechnology incubator, The Infectious Disease Research Institute (IDRI), to develop therapeutics against Ebola viruses. In 2016, they founded Vir Biotechnology with an initial capital of $150 million from various investors, including SoftBank and the Bill & Melinda Gates Foundation. The company received an additional capital injection of $250 million in 2018 and went public in the same year. Business model: Vir Biotechnology builds on its proprietary technology platform, which focuses on antibody identification. The company collaborates with various partners, including Biogen and Alnylam Pharmaceuticals, to utilize its technology for the development of therapeutics against infectious diseases such as COVID-19, influenza, rabbit fever, and the Zika virus. Vir Biotechnology also has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482. VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19 and is currently in phase 3 clinical trials. VIR-2703 is an inactive RNA vaccine developed for the prevention of COVID-19 and is currently in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine recently investigated in a phase 1/2a clinical trial. Divisions: Vir Biotechnology has focused on three main divisions: infectious diseases, immuno-oncology therapy, and neurodegenerative diseases. In the field of infectious diseases, the company works on the development of therapeutics against viruses such as COVID-19, respiratory syncytial virus (RSV), West Nile virus, and influenza virus. In the field of immuno-oncology therapy, the company works on the development of therapeutics against cancer. And in the field of neurodegenerative diseases, the company works on the development of therapeutics against diseases such as Alzheimer's and Parkinson's. Products: VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19. The antibody binds to the spike protein of the virus and blocks its interaction with ACE2 receptors in human cells. It is currently being tested in phase 3 clinical trials. VIR-2703 is a well-tolerated RNA vaccine developed for the prevention of COVID-19. It contains an inactivated form of the virus that stimulates the immune system to produce antibodies against the virus. It is currently being tested in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine developed to cover a broader spectrum of influenza viruses than conventional flu vaccines. The vaccine contains a combination of antibodies against various strains of the influenza virus and was recently investigated in a phase 1/2a clinical trial. Summary: Vir Biotechnology is a biopharmaceutical company focused on the development of therapeutics to combat infectious diseases. The company has a proprietary technology platform for antibody identification and collaborates with various partners to utilize this technology for the development of therapeutics against a variety of diseases. The company has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482, as well as research programs in the fields of immuno-oncology and neurodegeneration. The translation is: Vir Biotechnology Inc. is a biopharmaceutical company that focuses on the development of therapeutics to combat infectious diseases. The company was founded in 2016 by George Scangos, former CEO of Biogen, and Bob Nelsen, co-founder of Arch Venture Partners. History: Vir Biotechnology originated from a collaboration between Arch Venture Partners and the biotechnology incubator, The Infectious Disease Research Institute (IDRI), to develop therapeutics against Ebola viruses. In 2016, they founded Vir Biotechnology with an initial capital of $150 million from various investors, including SoftBank and the Bill & Melinda Gates Foundation. The company received an additional capital injection of $250 million in 2018 and went public in the same year. Business model: Vir Biotechnology builds on its proprietary technology platform, which focuses on antibody identification. The company collaborates with various partners, including Biogen and Alnylam Pharmaceuticals, to utilize its technology for the development of therapeutics against infectious diseases such as COVID-19, influenza, rabbit fever, and the Zika virus. Vir Biotechnology also has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482. VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19 and is currently in phase 3 clinical trials. VIR-2703 is an inactive RNA vaccine developed for the prevention of COVID-19 and is currently in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine recently investigated in a phase 1/2a clinical trial. Divisions: Vir Biotechnology has focused on three main divisions: infectious diseases, immuno-oncology therapy, and neurodegenerative diseases. In the field of infectious diseases, the company works on the development of therapeutics against viruses such as COVID-19, respiratory syncytial virus (RSV), West Nile virus, and influenza virus. In the field of immuno-oncology therapy, the company works on the development of therapeutics against cancer. And in the field of neurodegenerative diseases, the company works on the development of therapeutics against diseases such as Alzheimer's and Parkinson's. Products: VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19. The antibody binds to the spike protein of the virus and blocks its interaction with ACE2 receptors in human cells. It is currently being tested in phase 3 clinical trials. VIR-2703 is a well-tolerated RNA vaccine developed for the prevention of COVID-19. It contains an inactivated form of the virus that stimulates the immune system to produce antibodies against the virus. It is currently being tested in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine developed to cover a broader spectrum of influenza viruses than conventional flu vaccines. The vaccine contains a combination of antibodies against various strains of the influenza virus and was recently investigated in a phase 1/2a clinical trial. Summary: Vir Biotechnology is a biopharmaceutical company focused on the development of therapeutics to combat infectious diseases. The company has a proprietary technology platform for antibody identification and collaborates with various partners to utilize this technology for the development of therapeutics against a variety of diseases. The company has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482, as well as research programs in the fields of immuno-oncology and neurodegeneration. Vir Biotechnology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Frequently Asked Questions about Vir Biotechnology stock

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Vir Biotechnology

Our stock analysis for Vir Biotechnology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vir Biotechnology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.